DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma Epcoritamab With Rituximab + R2 Show Durable Responses In High-risk FL Patients Oct 17, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Subcutaneous Epcoritamab Is Well-Tolerated And Effective In Patients With R/R LBCL Oct 05, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Epcoritamab Shows Lasting Remissions in R/R LBCL Patients Oct 04, 2023
FL (Follicular Lymphoma),Lymphoma Tisagenlecleucel Proves Safe And Effective In Patients With R/R FL Sep 27, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma Epcoritamab + R2 Regimen Improves Outcomes In Patients With High‑Risk Follicular Lymphoma Sep 26, 2023
Lymphoma,MCL (Mantle Cell Lymphoma) MRD-driven Ibrutinib Discontinuation Shows Prolonged Undetectable MRD Sep 15, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Liso-cel Proves Safe And Effective For R/R LBCL Patients Aug 30, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Subcutaneous Epcoritamab Achieved Complete Remissions In R/R LBCL Aug 24, 2023